myocardial infarction

Unprotected trunk in diabetics: angioplasty with good long-term results but more revascularization

Original title: Coronary artery bypass graft versus percutaneous coronary intervention with drug-eluting stent implantation for diabetic patients with unprotected left main coronary artery disease: D-DELTA registry. Reference: Meliga Emanuele, et al. EuroIntervention 2013; 9:803-808 Diabetes increases cardiovascular risk events because of their involvement in diffuse form of the vessels, thereby generating more events and changes in revascularization strategy...

Everolimus -eluting stent to 3 years, most security was the key difference.

Original title: Everolimus-eluting stents in patients undergoing percutaneous coronary Intervention: Final 3-year results of the Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System in the Treatment of Subjects With de Novo Native Coronary Artery Lesions trial. Reference: Sorin J. Brener et al. Am Heart J 2013;0:1-8. The XIENCE stent (Abbott Vascular, Santa Clara, CA) is...

Primary angioplasty with 2nd generation drug-eluting stents

Original title: Stent thrombosis with second-generation drug-eluting stents compared with bare-metal stents: Network meta-analysis of primary percutaneous coronary intervention trials in ST-segment–elevation myocardial infarction. Reference: Circ Cardiovasc Interv. 2013; Epub ahead of print. To compare the safety and efficacy of 2nd generation drug-eluting stents (DES) versus bare metal stents (BMS) in the context of primary angioplasty was conducted...

Angioplasty or medical therapy in patients with documented ischemia

Original title: Percutaneous coronary intervention outcomes in patients with stable obstructive coronary artery disease and myocardial ischemia: A collaborative meta-analysis of contemporary randomized clinical trials. Reference: Stergiopoulos K el al. JAMA Intern Med 2013; DOI:10.1001/jamainternmed.2013 The amount in ischemic patients with stable coronary heart disease is associated with poor prognosis. However, it is unclear whether revascularization to reduce...

Drug eluting balloon followed BMS versus DES in de novo lesions

Original title: Elutax paclitaxel-eluting balloon followed by bare-metal stent compared with Xience V drug-eluting stent in the treatment of de novo coronary stenosis: A randomized trial. Reference: Francesco Liistro et al. Am Heart J 2013;166:920-6. Recently, drug eluting balloons (DEB) have emerged as a potential alternative to drug-eluting stents (DES). Paclitaxel is an appropriate drug for DEBs given...

Renal angioplasty versus medical treatment, no clinical benefit and only a modest help to control blood pressure

Original title: Stenting and Medical Therapy for Atherosclerotic Renal-Artery Stenosis. CORAL trial. Reference: Christopher J. Cooper et al. DOI: 10.1056/NEJMoa1310753   Between 1 and 5% of the hypertensive population has renal artery stenosis and in general, this is combined with peripheral and coronary vascular disease. The renal artery stenosis may result in hypertension, ischemic nephropathy, and multiple long-term...

Similar results of drug-eluting stents with biodegradable polymer versus permanent

Original title: Biodegradable Polymer Biolimus-Eluting Stent Versus Durable Polymer Everolimus-Eluting StentA Randomized, Controlled, Noninferiority Trial.NEXT trial. Reference: Masahiro Natsuaki et al. J Am CollCardiol 2013;62:181–90. Drug-eluting stents with biodegradable polymer were designed to counteract the long-term adverse effects on the vascular wall of permanent polymer.  This prospective, multicenter, randomized, non-inferiority design study, compared the biolimus eluting stent with...

Looking for the best anti-aggregation scheme after TAVI

Original title: Comparison of Two Antiplatelet Therapy Strategies in Patients Undergoing Transcatheter Aortic Valve Implantation. Reference: Eric Durand et al. Am J Cardiol 2013, et al. Percutaneous aortic valve replacement has been shown to be superior to medical treatment in inoperable patients and not inferior to surgery in high-risk patients. Anti-platelet therapy in these patients is usually...

Low cardiac mortality with bivalirudin beyond the reduction in major bleeding

Original title: Reduction in Cardiac Mortality with Bivalirudin in Patients With and Without Major Bleeding: The HORIZONS-AMI Trial. Reference: Gregg W. Stone et al. J Am Coll Cardiol. Epub ahead of print The HORIZONS -AMI study included 3602 patients experiencing ST  segment elevation myocardial infarction received primary angioplasty, resulting in lower mortality at 30 days and three years...

Infarct size reduction to 30 days could result in clinical benefit at one year

Original title: Intralesional abciximab and thrombus aspiration in patients with large anterior myocardial infarction: One-year results from the INFUSE-AMI trial. Reference: Stone GW et al. Circ Cardiovasc Interv. 2013;Epub ahead of print.   The intra-coronary infusion of Abciximab added to thromboaspiration seems to improve outcomes at one year in patients undergoing primary angioplasty for ST-segment elevation with anterior...

Top